SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta Personals rollout and its ACH-linked payment features, alongside Visa Direct and Bivo integrations, are driving discussion about the networks real-world financial rails. Bulls see the launches as progress toward adoption, while skeptics point to weak price action and say sustained transaction volume is still needed to prove demand.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

ALMs steep pullback is driving discussion, with traders attributing pressure to broader risk-off conditions, higher yields and weakness across critical-minerals stocks, while some question support and the Sangdong ramp-up. Bulls view the decline as a buying opportunity based on Almontys tungsten supply-chain position and production growth, while others warn that cyclical downside may continue.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as traders debate whether the gold-miner pullback is nearing a bottom, with gold prices and inflation-driven Fed-rate expectations shaping the discussion. Bullish views on gold and miners longer-term prospects compete with technical warnings that Barricks correction could extend lower.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

A sharp LINK rebound followed by renewed selling has fueled debate over whether the move can break out or will fade. Dip buyers point to Chainlinks institutional and tokenization integrations, while skeptics highlight repeated pullbacks and question whether network adoption translates into value for the token.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is drawing attention as traders look for a rebound in gold and gold-mining shares, citing improving chart signals and the possibility that the recent metals pullback is bottoming. The community is largely bullish on a gold recovery, though some note that interest-rate expectations and golds volatility could continue to pressure miners.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with traders focusing mainly on swings in the Nasdaq market and debating whether broad tech weakness signals a deeper correction or a buying opportunity. Other recurring themes include Nasdaqs plans for extended-hours trading and tokenized equities, plus criticism and support around its listing and index-inclusion rules.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

A live governance proposal to increase INJs deflation rate is fueling attention, alongside discussion of ongoing buybacks and burns, staking, and Injectives RWA and institutional ambitions. Bullish traders see these as supply and adoption tailwinds, while skeptics point to the prolonged downtrend and criticize repetitive promotion of ecosystem memecoins.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is drawing attention alongside strength in defense stocks, with traders pointing to defense-spending expectations and potential Pentagon awards, including progress on the B-21 program. Some see room for a recovery after recent weakness, while others are waiting for stronger confirmation of a sustained move.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturuss interim Phase 2 update for its OTC deficiency therapy, ARCT-810, and the introduction of its LUNAR 2.0 delivery platform are driving discussion, alongside its myNEO acquisition. Some traders view the biomarker findings and platform upgrade as encouraging, while others argue that shifting to a new candidate could delay progress and that the news fell short of a major catalyst.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Bets on a Nasdaq pullback are driving attention, with traders citing concerns about stretched AI and tech valuations, rising yields and hawkish Fed risks, alongside broader market and geopolitical uncertainty. Some see SQQQ as a hedge or short-term trade, while others warn that its daily leverage and decay make it risky to hold as the market may keep rising.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Vyome Holdings, Inc. (Nasdaq: HIND) (Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303...

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Vyome Holdings, Inc. (Nasdaq: HIND) (Vyome or the Company), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, today announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief...

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Vyome Holdings, Inc. (Nasdaq: HIND, Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings...

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome Holdings, Inc. (NASDAQ: HIND) (Vyome or the Company), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a...

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Holdings, Inc. (Nasdaq: HIND)(Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said...

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (Impetis), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK...

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer...

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

Vyome Holdings Inc.

HIND Stock Rallies 70% Pre-Market Today – Find Out Why

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.87
Prev Close	$1.91
Open	$1.89
Dividend Yield	0.00%
50-Day Moving Average	$2.09
Beta	0.17
Avg. Volume	20,195.31
PE Ratio	-0.53

52-Week High	$6.56
52-Week Low	$1.75
Market Capitalization	$13.12M
EPS (Annual)	-$4.75
Price to Book	2.17
Revenue Per Employee	$17,761.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIND Fundamentals